Here, we describe a novel polymer platform suitable for efficient diagnostics and potential theranostics based on 89Zr-labeled N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer conjugates. A set of polymers differing in molecular weight with either low dispersity or high dispersity were designed and synthesized and their biodistribution in vivo was successfully and precisely observed over 72 h. Moreover, the feasibility of two imaging techniques, fluorescence imaging (FI) and positron emission tomography (PET), was compared using labeled polymer conjugates. Both methods gave comparable results thus showing the enhanced diagnostic potential of the prepared polymer-dye or polymer-chelator-89Zr constructs. The in vivo and ex vivo PET/FI studies indicated that the dispersity and molecular weight of the linear HPMA polymers have a significant influence on the pharmacokinetics of the polymer conjugates. The higher molecular weight and narrower distribution of molecular weights of the polymer carriers improve their pharmacokinetic profile for highly prolonged blood circulation and enhanced tumor uptake. Moreover, the same polymer carrier with the anticancer drug doxorubicin bound by a pH-sensitive hydrazone bond showed higher cytotoxicity and cellular uptake in vitro. Therefore, HPMA copolymers with low dispersity and a molecular weight near the limit of renal filtration can be used as highly efficient polymer carriers of tumor-targeted therapeutics or for theranostics with minimal side effects.

Departments of Radiology and Medical Physics University of Wisconsin Madison Madison Wisconsin USA

Institute of Macromolecular Chemistry Czech Academy of Sciences Heyrovsky Sq 2 Prague 6 162 06 Czech Republic

Materials Science Program University of Wisconsin Madison Madison Wisconsin USA

Materials Science Program University of Wisconsin Madison Madison Wisconsin USA and Departments of Radiology and Medical Physics University of Wisconsin Madison Madison Wisconsin USA and University of Wisconsin Carbone Cancer Center Madison Wisconsin USA

Zobrazit více v PubMed

Dozono H, Yanazume S, Nakamura H, Etrych T, Chytil P, Ulbrich K, Fang J, Arimura T, Douchi T, Kobayashi H, Ikoma M, Maeda H. HPMA Copolymer-Conjugated Pirarubicin in Multimodal Treatment of a Patient with Stage IV Prostate Cancer and Extensive Lung and Bone Metastases. Targeted oncology. 2015 PubMed

Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, Boivin C, Hesslewood S, Twelves C, Blackie R, Schatzlein A, Jodrell D, Bissett D, Calvert H, Lind M, Robbins A, Burtles S, Duncan R, Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34:1629–36. PubMed

Maeda H, Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 1989;6:193–210. PubMed

Etrych T, Mrkvan T, Chytil P, Koňák Č, Říhová B, Ulbrich K. N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation. J Appl Polym Sci. 2008;109:3050–3061.

Etrych T, Kovář L, Strohalm J, Chytil P, Říhová B, Ulbrich K. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. J Controlled Release. 2011;154:241–8. PubMed

Etrych T, Šubr V, Strohalm J, Šírová M, Říhová B, Ulbrich K. HPMA copolymer-doxorubicin conjugates: The effects of molecular weight and architecture on biodistribution and in vivo activity. J Controlled Release. 2012;164:346–54. PubMed

Scales CW, Vasilieva YA, Convertine AJ, Lowe AB, McCormick CL. Direct, Controlled Synthesis of the Nonimmunogenic, Hydrophilic Polymer, Poly(N-(2-hydroxypropyl)methacrylamide) via RAFT in Aqueous Media. Biomacromolecules. 2005;6:1846–1850. PubMed

Yanjarappa MJ, Gujraty KV, Joshi A, Saraph A, Kane RS. Synthesis of copolymers containing an active ester of methacrylic acid by RAFT: controlled molecular weight scaffolds for biofunctionalization. Biomacromolecules. 2006;7:1665–70. PubMed

Tucker BS, Sumerlin BS. Poly(N-(2-hydroxypropyl) methacrylamide)-based nanotherapeutics. Polym Chem-Uk. 2014;5:1566–1572.

Yang J, Kopeček J. MACROMOLECULAR THERAPEUTICS. J Controlled Release. 2014;0:288–303. PubMed PMC

Gregory A, Stenzel MH. Complex polymer architectures via RAFT polymerization: From fundamental process to extending the scope using click chemistry and nature’s building blocks. Progress in Polymer Science. 2012;37:38–105.

Chytil P, Šírová M, Koziolová E, Ulbrich K, Říhová B, Etrych T. The comparison of in vivo properties of water-soluble HPMA-based polymer conjugates with doxorubicin prepared by controlled RAFT or free radical polymerization. Physiol Res. 2015;64:41–49. PubMed

Lammers T, Kuhnlein R, Kissel M, Šubr V, Etrych T, Pola R, Pechar M, Ulbrich K, Storm G, Huber P, Peschke P. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. J Control Release. 2005;110:103–18. PubMed

Hoffmann S, Vystrčilová L, Ulbrich K, Etrych T, Caysa H, Mueller T, Mäder K. Dual Fluorescent HPMA Copolymers for Passive Tumor Targeting with pH-Sensitive Drug Release: Synthesis and Characterization of Distribution and Tumor Accumulation in Mice by Noninvasive Multispectral Optical Imaging. Biomacromolecules. 2012;13:652–663. PubMed

Chytil P, Koziolova E, Janouskova O, Kostka L, Ulbrich K, Etrych T. Synthesis and Properties of Star HPMA Copolymer Nanocarriers Synthesised by RAFT Polymerisation Designed for Selective Anticancer Drug Delivery and Imaging. Macromol Biosci. 2015;15:839–50. PubMed

Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008;49(Suppl 2):113–28. PubMed

Goel S, England CG, Chen F, Cai W. Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics. Adv Drug Deliv Rev. 2016 PubMed PMC

Šubr V, Ulbrich K. Synthesis and properties of new N-(2-hydroxypropyl)methacrylamide copolymers containing thiazolidine-2-thione reactive groups. React Funct Polym. 2006;66:1525–1538.

Chytil P, Etrych T, Kříž J, Šubr V, Ulbrich K. N-(2-Hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin for cell-specific or passive tumour targeting. Synthesis by RAFT polymerisation and physicochemical characterisation. Eur J Pharm Sci. 2010;41:473–482. PubMed

Ulbrich K, Etrych T, Chytil P, Jelínková M, Říhová B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target. 2004;12:477–489. PubMed

Šácha P, Knedlík T, Schimer J, Tykvart J, Parolek J, Navrátil V, Dvořáková P, Sedlák F, Ulbrich K, Strohalm J, Majer P, Šubr V, Konvalinka J. iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angew Chem Int Ed. 2016;55:2356–60. PubMed PMC

Perrier S, Takolpuckdee P, Mars CA. Reversible addition-fragmentation chain transfer polymerization: End group modification for functionalized polymers and chain transfer agent recovery. Macromolecules. 2005;38:2033–2036.

Etrych T, Chytil P, Jelínková M, Říhová B, Ulbrich K. Synthesis of HPMA Copolymers Containing Doxorubicin Bound via a Hydrazone Linkage. Effect of Spacer on Drug Release and in vitro Cytotoxicity. Macromol Biosci. 2002;2:43–52.

Hong H, Severin GW, Yang Y, Engle JW, Zhang Y, Barnhart TE, Liu G, Leigh BR, Nickles RJ, Cai W. Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105. Eur J Nucl Med Mol Imaging. 2012;39:138–48. PubMed PMC

Chen F, Goel S, Valdovinos HF, Luo H, Hernandez R, Barnhart TE, Cai W. In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles. ACS nano. 2015;9:7950–9. PubMed PMC

Deri MA, Zeglis BM, Francesconi LC, Lewis JS. PET Imaging with (89)Zr: From Radiochemistry to the Clinic. Nucl Med Biol. 2013;40:3–14. PubMed PMC

Using surface plasmon resonance, capillary electrophoresis and diffusion-ordered NMR spectroscopy to study drug release kinetics

Evaluation of linear versus star-like polymer anti-cancer nanomedicines in mouse models

HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery

Polymer Nanomedicines with Ph-Sensitive Release of Dexamethasone for the Localized Treatment of Inflammation

HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours

Polymer Cancerostatics Containing Cell-Penetrating Peptides: Internalization Efficacy Depends on Peptide Type and Spacer Length

Fluorescence Imaging as a Tool in Preclinical Evaluation of Polymer-Based Nano-DDS Systems Intended for Cancer Treatment

Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3